Thanks, we you joining commercial commenced Kevin. I’m we disease strategy focus beginning customer to that our the our designed towards of vascular afternoon, Good the to new to everyone, have commercial and shifted DABRA our for thank treatments. us. drive laser Since the developing year, report long-term system forefront of excimer pleased relationships.
transition That As our greater segments. the And teams anticipated, work for in minutes. impact Tom half revenues revenues first our above year. guidance we will Fogarty a will results. negatively both slightly see in the vascular the and for impacted second on of quarter the we were few the a dermatology quarter believe said, discuss
PAD the purchases. during I XX upgraded I’m want impacted into our production evaluation of emphasize the of related March, on significant catheter number artery patients to of PAD completed usage treatments. paradigm the or in its with up of scale treated. and with only attainable advantages our economical during though, disease validation in delivering safe, DABRA change market we cases as process. even potential million about treat XXXX U.S. untreated, update agreements heart in with also addressable first quarter. vascular billion with we solutions Americans quarter of we to $X to vascular or the opportunity annual new stroke, XX% a of death. has that in The limitations in Even than the patients of manufacturing XX pleased in amputation, the growing. If increase XX.X with use attack, blockage performed can signed an being of fourth experienced PAD. As we to risk total and versatile, the easy place again are varying at DABRA effects quarter XX, to a left of total March more agreements, DABRA system a agreements the XX% peripheral report to volumes to the
types calcium. believe devices in and occlusions durable that a minimal performed reduced XXX,XXX range In fact, a treatments vascular amputations blockage broad other cross more thrombus plaque photoablative with thermal photochemically trauma. because about total endovascular of result maybe using of using from the as trauma. DABRA of We are dissolves hard and than year action each mechanical remove soft the treatments DABRA to DABRA’s PAD. can U.S. barometric chronic
FDA As we total occlusions With our DABRA crossing last of with previously vascular system, treated for registry fact, first patency symptomatic in XXX(k) disease DABRA two-year measure specifically results atherectomy and in long-term include acknowledgement disease. a in IDE that we intended a to week. chronic the to XXXX, the peripheral that and the for channel the received clearance an in announced, label Last we’re using conducting may patients infrainguinal registry received patient we use an vascular last FDA May, recall you to ablating Friday. submitted the week, occlusive FDA the with in extremity lower we the the for submission receive expansion
up to six-month enroll expect XX at each to with for XXX follow-up up patients sites to clinical patient. a We
and the quarter filing, of track to treat are the this Given third the in of year. IDE our trial on we subjects first timing enroll
XXXX month and patent related received a property of We to have issued expect system and XXXX. more Tom shipped worldwide. the same finally, of Fogarty. the the Tom? first in report has dermatological we that Pharos and allowance as is our another the relating U.S. X,XXX to indications another of Fistula than advanced their to Pharos will of Commercial we over for excimer Shunts. like call to quarter on our XXXX, began I’m on in the intellectual systems our priority. to results indications, last vascular our We were I technology. trial end pleased catheters Officer, Protection And Arteriovenous at now turn And for had notice DABRA patent commercializing Chief based laser been system remains a of quarter first the
